drugset / Trial / NCT05869669
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase 2
Completed
159 enrolled
EIP Pharma Inc
CervoMed, Inc. · collabNational Institute on Aging (NIA) · collabWorldwide Clinical Trials · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2025-05-29
- Completion
- 2025-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neflamapimod | Small molecule | 40 mg | — |